| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers K > Headlines for Keryx Biopharmaceuticals, Inc. > News item |
Keryx says preclinical studies demonstrate effectiveness of KRX-0401 against multiple myeloma cells
By E. Janene Geiss
Philadelphia, Dec. 8 - Keryx BioPharmaceuticals, Inc. said Thursday that the results of several preclinical experiments demonstrate the effectiveness of KRX-0401 (perifosine) against multiple myeloma cells.
KRX-0401, the company's lead oncology compound under development, is a novel oral anticancer agent that modulates Akt and several other important signal transduction pathways, including MAP kinase and JNK, according to a company news release.
KRX-0401 is currently being evaluated in phase 2 clinical trials as a single agent and in combination with other anti-cancer agents across several tumor types.
"We are excited that the preclinical results of perifosine, alone and in combination with other conventional agents, suggest this oral agent, with a novel mechanism of action, may offer a new approach to treatment-resistant patients with multiple myeloma. We look forward to moving perifosine into planned clinical trials in the near future," Kenneth C. Anderson, director of the Dana Farber Cancer Institute's Jerome Lipper Multiple Myeloma Center and chief of the division of hematologic neoplasia, said in the release.
This research and an additional six studies of KRX-0401 will be presented at the Society of Hematology annual meeting in Atlanta this weekend.
"This is the first time that perifosine has been evaluated in non-solid tumors and the results are quite compelling, even though they are still preclinical. We will launch human studies in the very near future to see if the beneficial effects seen in these preclinical models can be replicated in patients with multiple myeloma," Craig Henderson, president of Keryx, said in the release.
KRX-0401 is in-licensed by Keryx from Aeterna Zentaris, Inc. in the United States, Canada and Mexico, officials said.
Keryx is a New York City biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.